Skip to content

Study · Measured the body's own peptide · 2023

5 results

Circulating levels of mitochondrial oxidative stress-related peptides MOTS-c and Romo1 in stable COPD: A cross-sectional study.

Amado CA, Martín-Audera P, Agüero J, Lavín BA, Guerra AR, Boucle D, Ferrer-Pargada D, Berja A, Martín F, Casanova C, García-Unzueta M

Frontiers in medicine8 Feb 2023Cited by 9 (Europe PMC)

PMID36844198 (opens in a new tab)PMCIDPMC9944395 (opens in a new tab)DOI10.3389/fmed.2023.1100211 (opens in a new tab)PepBankPUB-36844198
Download PDFPubMedAsk about this study
Jump to 5 results

Summary

BackgroundMOTS-c and Romo1 are mitochondrial peptides that are modulated by oxidative stress. No previous studies have explored circulating levels of MOTS-c in patients with chronic obstructive pulmonary disease (COPD).MethodsWe enrolled 142 patients with stable COPD and 47 smokers with normal lung function in an observational cross-sectional study. We assessed serum levels of both MOTS-c and Romo1 and associated these findings with clinical characteristics of COPD.ResultsCompared with smokers with normal lung function, patients with COPD had lower levels of MOTS-c (p = 0.02) and higher levels of Romo1 (p = 0.01). A multivariate logistic regression analysis revealed that above-median MOTS-c levels were positively associated with Romo1 levels (OR 1.075, 95% CI 1.005-1.150, p = 0.036), but no association was found with other COPD characteristics. Below-median levels of circulating MOTS-c were associated with oxygen desaturation (OR 3.25 95% CI 1.456-8.522, p = 0.005) and walking p = 0.018) in six-minute walk test. Above-median levels of Romo1 were positively associated with current smoking (OR 2.756, 95% CI 1.133-6.704, p = 0.025) and negatively associated with baseline oxygen saturation (OR 0.776 95% CI 0.641-0.939, p = 0.009).ConclusionsReduced levels of circulating MOTS-c and increased levels of Romo1 were detected in patients diagnosed with COPD. Low levels of MOTS-c were associated with oxygen desaturation and poorer exercise capacity using 6 min walk test. Romo1 was associated with current smoking and baseline oxygen saturation.Trial registrationwww.clinicaltrials.gov; No.: NCT04449419; URL: www.clinicaltrials.gov. Date of registration: June 26, 2020.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study5

No result from this study comes from a test of the peptide.

Natural levels measured5

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelObservational studyOther

    In adults with stable COPD, serum MOTS‑c levels were lower than in smokers with normal lung function.

    In plain wordsPeople with stable COPD had lower levels of the body's own MOTS‑c in blood than smokers with normal lungs.

    Peptide
    MOTS-c
    Outcome
    DecreaseSerum MOTS-c in COPD vs smokers with normal lung function
    Study

    n = 189

    Comparator
    Smokers with normal lung function
    Outcome group
    Mitochondrial function · Respiratory

    Source sentences

    Summary
    Compared with smokers with normal lung function, patients with COPD had lower levels of MOTS-c (p = 0.02) and higher levels of Romo1 (p = 0.01).
    1 context sentence
    Summary · context
    We enrolled 142 patients with stable COPD and 47 smokers with normal lung function in an observational cross-sectional study.

    This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.

  2. 02HumanEndogenous levelObservational studyOther

    In adults with stable COPD, above-median MOTS‑c levels were positively associated with Romo1 levels.

    In plain wordsIn people with COPD, higher levels of the body's own MOTS‑c were linked to higher levels of another marker, Romo1.

    Peptide
    MOTS-c
    Outcome
    IncreaseAssociation of above-median MOTS-c with Romo1
    Study

    n: not reported in source

    Outcome group
    Mitochondrial function · Respiratory

    Measurements

    OR
    1.075 ratio
    above-median MOTS-c and Romo1

    Source sentences

    Summary
    A multivariate logistic regression analysis revealed that above-median MOTS-c levels were positively associated with Romo1 levels (OR 1.075, 95% CI 1.005-1.150, p = 0.036)
    1 context sentence
    Summary · context
    We enrolled 142 patients with stable COPD and 47 smokers with normal lung function in an observational cross-sectional study.

    This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.

  3. 03HumanEndogenous levelObservational studyOther

    In adults with stable COPD, MOTS‑c levels showed no association with other COPD characteristics.

    In plain wordsIn people with COPD, the body's own MOTS‑c was not linked to other COPD features.

    Peptide
    MOTS-c
    Outcome
    No significant changeAssociation of MOTS-c with other COPD characteristics
    Study

    n: not reported in source

    Outcome group
    Mitochondrial function · Respiratory

    Source sentences

    Summary
    but no association was found with other COPD characteristics.
    1 context sentence
    Summary · context
    We enrolled 142 patients with stable COPD and 47 smokers with normal lung function in an observational cross-sectional study.

    This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.

  4. 04HumanEndogenous levelObservational studyOther

    In adults with stable COPD, below-median MOTS‑c levels were associated with higher odds of oxygen desaturation in the six-minute walk test.

    In plain wordsIn people with COPD, low levels of the body's own MOTS‑c were linked to oxygen drops during a walking test.

    Peptide
    MOTS-c
    Outcome
    IncreaseBelow-median MOTS-c and oxygen desaturation in six-minute walk test
    Study

    n: not reported in source

    Outcome group
    Mitochondrial function · Respiratory

    Measurements

    OR
    3.25 ratio
    oxygen desaturation

    Source sentences

    Summary
    Below-median levels of circulating MOTS-c were associated with oxygen desaturation (OR 3.25 95% CI 1.456-8.522, p = 0.005)
    1 context sentence
    Summary · context
    We enrolled 142 patients with stable COPD and 47 smokers with normal lung function in an observational cross-sectional study.

    This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.

  5. 05HumanEndogenous levelObservational studyOther

    In adults with stable COPD, below-median MOTS‑c levels were associated with higher odds of walking less than 350 meters in the six-minute walk test.

    In plain wordsIn people with COPD, low levels of the body's own MOTS‑c were linked to shorter walking distance.

    Peptide
    MOTS-c
    Outcome
    IncreaseBelow-median MOTS-c and walking under 350 meters
    Study

    n: not reported in source

    Outcome group
    Exercise and physical function · Respiratory

    Measurements

    OR
    3.246 ratio
    walking <350 m

    Source sentences

    Summary
    Below-median levels of circulating MOTS-c were associated with oxygen desaturation (OR 3.25 95% CI 1.456-8.522, p = 0.005) and walking p = 0.018) in six-minute walk test.
    1 context sentence
    Summary · context
    We enrolled 142 patients with stable COPD and 47 smokers with normal lung function in an observational cross-sectional study.

    This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.